spacer
home > epc > spring 2002 > transformation from paper to electronic clinical trials - the site perspective
PUBLICATIONS
European Pharmaceutical Contractor

Transformation from Paper to Electronic Clinical Trials - The Site Perspective

Rising competitive pressures are forcing the drug development process to work at a faster and more efficient pace, shortening development cycles and increasing the demand for shorter data collection times. In response to this challenge, according to the Forrester report (1) in July 2001, more than 50 per cent of trial professionals would prefer to conduct clinical trials using web-enabled systems in place of paper and two-thirds think sponsors should make this change happen now.

The first stage in the successful implementation of a web-based trial process at the clinical investigation site is providing encouragement for the evolution of the users' mindset. If the process is continuously equated to a paper-based trial, problems will inevitably arise. We need to promote a new working environment at the user level, and introduce the new process at a rate and level appropriate to that of the user's previous experience, current resources and organisational culture. It is preferable to integrate the electronic concept gradually into the existing practice - this is an intricate challenge!

To maximise efficiency in a paper trial, the standard site's working ethos has evolved to working with batches of patient data. In contrast, e-trials often dictate that immediate data entry is required - resulting in the co-ordinator working on a 'per patient' basis. The difference in processing requirements between paper and electronic studies should be resolved during the study initiation or site set-up, to prevent unnecessary conflicting expectations within the study teams. Communication charts are particularly useful as more individuals become involved in e-trials (including technical support, help desk personnel and clinical staff).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Paul Webb, Commercial and Operations Director, and Nigel Trim, Managing Director of MATRIX contract research Limited

Paul Webb was appointed Commercial and Operations Director in 2000 with responsibility for bringing improved technology utilisation to MATRIX contract research Limited and its clients. He has over 12 years' experience of EDC, change management and business process re-engineering, gained through consultancy work with the world's leading aerospace and defence corporations.

Nigel Trim, a Pharmacologist, is Managing Director of MATRIX contract research Limited. He has previous experience as managing director of a medical IT company and of senior management in International Sales and Marketing, with particular experience in the use of the Internet, clinical research, the management of direct sales, global distribution networks, and in and out-licensing.


spacer
Paul Webb
spacer
spacer
spacer
Nigel Trim,
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CRF Health Opens Registration for eCOA Forum Scientific Sessions

Leading global provider of electronic clinical outcome assessment (eCOA) solutions, CRF Health, has opened registration for its 2015 eCOA Forum Scientific Sessions European event, which will return to the University of Oxford on 27-28 October.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

MAGHREB PHARMA Expo

29 September - 1 October 2015, Hilton Hotel, Algiers (Algeria)

MAGHREB PHARMA Expo is the largest pharmaceutical technology tradeshow in Africa
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement